Pancreatic Cystic Lesions News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mauna Kea Technologies: Cellvizio Combined with Artificial Intelligence Outperforms Standard of Care for Pancreatic Cyst Diagnosis and Risk Stratification
New peer-reviewed systematic meta-analysis puts Cellvizio diagnostic accuracy at 99%
Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced the publication of a peer-reviewed study on pancreatic cystic lesion (PCL) risk stratification using artificial intelligence (AI) models for nCLE image classification and the publication of a new peer-reviewed meta-analysis on endoscopic ultrasound (EUS) guided nCLE for PCL evaluation.
The majority of PCLs incidentally found in the population represent intraductal papillary mucinous neoplasms (IPMNs), a precursor of pancreatic adenocarcinoma. Current standard of care relies on a combination of clinical history, ....

United States , France General , Robertl Gershon , Thomas Grojean , Mike Piccinino , French Financial Markets Authority Autorit , Kea Technologies , Gastrointestinal Endoscopy , Confocal Laser Endomicroscopy , Pancreatic Cystic Lesions , Systematic Review , Clinical Gastroenterology , Chief Executive Officer , Mauna Kea , Mauna Kea Technologies , French Financial Markets Authority , Cap Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , கீ தொழில்நுட்பங்கள் , இரைப்பை குடல் எண்டோஸ்கோபி , முறையான விமர்சனம் , மருத்துவ இரைப்பை குடல் , தலைமை நிர்வாகி அதிகாரி , ம Una னா கீ , ம Una னா கீ தொழில்நுட்பங்கள் ,